Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients

British Journal of Clinical Pharmacology

Volumn 67, Issue 2, 2009, Pages 216-227

  Pettersen, Géraldine ^b,c   Mouksassi, Mohamad Samer ^b,f,g   Théorêt, Yves ^b,e,g   Labbé, Line ^b,g   Faure, Christophe ^d   Nguyen, Bao ^a   Litalien, Catherine ^a,b,c,g  

^a UNIVERSITY OF MONTREAL   (Canada)

^b Department of Paediatrics   (Canada)

^c Division of Paediatric Critical Care   (Canada)

^d Division of Gastroenterology   (Canada)

^e Department of Biochemistry ^*  (Canada)

^f PHARSIGHT CORPORATION   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Critical care; Paediatrics; Pantoprazole; Population pharmacokinetics; Systemic inflammatory response syndrome

Indexed keywords

CYTOCHROME P450 2C19; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADOLESCENT; ARTICLE; BODY WEIGHT; CHILD; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG ELIMINATION; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFANT; INTENSIVE CARE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NEWBORN; PEDIATRIC HOSPITAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POPULATION MODEL; PRIORITY JOURNAL; STOMACH ACID SECRETION; STRESS ULCER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; TREATMENT OUTCOME;

EID: 61349129000     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03328.x     Document Type: Article

References (65)

1. Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med 2004 32 : 2008 13.
2. Persad R, MacDonald P, AlSaleem B, Issenman R. Intravenous pantoprazole use in a pediatric tertiary care center. Can J Gastroenterol 2003 17 (Suppl. A 144A (abstract 253).
3. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc 2007 82 : 286 96.
4. Bussières JF, Lebel D, Prot-Labarthe S, Bouche V, Nguyen B, Litalien C. Nouvelle méthode de revue d'utilisation des médicaments: application au pantoprazole intraveineux en réanimation pédiatrique [New method for drug utilization review: example of intravenous pantoprazole in the pediatric intensive care unit J Pharm Clin 2007 26 : 101 9.
5. Morgan D. Intravenous proton pump inhibitors in the critical care setting. Crit Care Med 2002 30 : S369 72.
6. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995 9 : 363 78.
7. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997 17 : 22 37.
8. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994 106 : 60 4.
9. Netzer P, Gaia C, Sandoz M, Huluk T, Gut A, Halter F, Husler J, Inauen W. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999 94 : 351 7.
10. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annu Rev Pharmacol Toxicol 1995 35 : 277 305.
11. Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 1993 45 : 367 71.
12. Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 2002 57 : 595 601.
13. Lins RL, De Clercq I, Hartmann M, Huber R, Bliesath H, Lühmann R, Wurst W. Pharmacokinetics of the proton pump inhibitor pantoprazole in patients with severe renal impairment. Gastroenterology 1994 106 : A126 (abstract).
14. Naesdal J, Andersson T, Bodemar G, Larsson R, Regardh CG, Skanberg I, Walan A. Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. Clin Pharmacol Ther 1986 40 : 344 51.
15. Kliem V, Bahlmann J, Hartmann M, Huber R, Luhmann R, Wurst W. Pharmacokinetics of pantoprazole in patients with end-stage renal failure. Nephrol Dial Transpl 1998 13 : 1189 93.
16. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000 14 : 963 78.
17. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006 29 : 769 84.
18. Dunn A, White CM, Reddy P, Quercia RA, Chow MS. Delivery of omeprazole and lansoprazole granules through a nasogastric tube in vitro. Am J Health Syst Pharm 1999 56 : 2327 30.
19. Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005 44 : 441 66.
20. Ritz MA, Fraser R, Tam W, Dent J. Impacts and patterns of disturbed gastrointestinal function in critically ill patients. Am J Gastroenterol 2000 95 : 3044 52.
21. Baker DE. Intravenous proton pump inhibitors. Rev Gastroenterol Disord 2006 6 : 22 34.
22. Ferron GM, Schexnayder S, Marshall JD, Blumer J, Rodarte A, Abell MW, Mako B, Fraga P, Getsy J, Paul J. Pharmacokinetics of IV pantoprazole in pediatric patients. Clin Pharmacol Ther 2003 73 : P37 (abstract PII-30).
23. Kearns GL, Ferron GM, James LP, Blumer JL, Gaedigk A, Mayer P, Abel M, Getsy JA, Leeder JS, Paul J. Pantoprazole disposition in pediatrics. Clin Pharmacol Ther 2003 73 : P38 (abstract PII-35).
24. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991 20 : 38 49.
25. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006 44 : 297 302.
26. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983 24 : 270 6.
27. Faure C, Michaud L, Shaghaghi EK, Popon M, Laurence M, Mougenot JF, Hankard R, Navarro J, Jacoz-Aigrain E. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001 15 : 1397 402.
28. Faure C, Michaud L, Shaghaghi EK, Popon M, Turck D, Navarro J, Jacqz-Aigrain E. Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. J Pediatr Gastroenterol Nutr 2001 33 : 144 8.
29. Gremse D, Winter H, Tolia V, Gunasekaran T, Pan WJ, Karol M, Chiu YL, Pilmer B, Book L. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002 35 (Suppl. 4 S319 26.
30. Kearns GL, Winter HS. Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. J Pediatr Gastroenterol Nutr 2003 37 (Suppl. 1 S52 9.
31. Olsen KM, Bergman KL, Kaufman SS, Rebuck JA, Collier DS. Omeprazole pharmacodynamics and gastric acid suppression in critically ill pediatric transplant patients. Pediatr Crit Care Med 2001 2 : 232 7.
32. Tran A, Rey E, Pons G, Pariente-Khayat A, D'Athis P, Sallerin V, Dupont C. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002 71 : 359 67.
33. Pettersen G, Faure C, Litalien C, Theoret Y, Mouksassi MS, Nguyen B, Labbe L, Proietti A. Therapeutic failure of a single intravenous dose of pantoprazole in young intensive care children. Crit Care Med 2005 33 : A170 (abstract 232-T).
34. Chaibou M, Tucci M, Dugas MA, Farrell CA, Proulx F, Lacroix J. Clinically significant upper gastrointestinal bleeding acquired in a pediatric intensive care unit: a prospective study. Pediatrics 1998 102 : 933 8.
35. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006 45 : 1077 97.
36. PMS-Pantoprazole monograph. Pharmascience Inc., Montreal, Canada, 2007.
37. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM Users Guides (1989-2006). Icon Development Solutions, Ellicott City, Maryland, USA, 2006.
38. Cleveland WS, Devlin SJ. Locally-weighted regression: an approach to regression analysis by local fitting. J Am Statist Assoc 1988 83 : 596 610.
39. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005 6 : 2 8.
40. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr 2006 165 : 741 6.
41. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001 28 : 171 92.
42. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999 59 : 19 29.
43. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 2006 165 : 819 29.
44. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004 308 : 965 74.
45. Bleau AM, Maurel P, Pichette V, Leblond F, du Souich P. Interleukin-1beta, interleukin-6, tumour necrosis factor-alpha and interferon-gamma released by a viral infection and an aseptic inflammation reduce CYP1A1, 1A2 and 3A6 expression in rabbit hepatocytes. Eur J Pharmacol 2003 473 : 197 206.
46. Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 2005 1 : 629 40.
47. Carcillo JA, Doughty L, Kofos D, Frye RF, Kaplan SS, Sasser H, Burckart GJ. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003 29 : 980 4.
48. Haas CE, Kaufman DC, Jones CE, Burstein AH, Reiss W. Cytochrome P450 3A4 activity after surgical stress. Crit Care Med 2003 31 : 1338 46.
49. Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest 1996 109 : 1033 7.
50. Ferron GM, Preston RA, Noveck RJ, Pockros P, Mayer P, Getsy J, Turner M, Abell M, Paul J. Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Clin Ther 2001 23 : 1180 92.
51. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003 63 : 101 33.
52. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996 51 : 460 82.
53. Huber R, Hartmann M, Bliesath H, Luhmann R, Steinijans VW, Zech K. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996 34 : 185 94.
54. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003 349 : 1157 67.
55. Takahashi H, Ishikawa S, Nomoto S, Nishigaki Y, Ando F, Kashima T, Kimura S, Kanamori M, Echizen H. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 2000 68 : 541 55.
56. Yacyshyn BR, Thomson AB. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion 2002 66 : 67 78.
57. Conrad SA. Acute upper gastrointestinal bleeding in critically ill patients: causes and treatment modalities. Crit Care Med 2002 30 : S365 8.
58. Green FW Jr., Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978 74 : 38 43.
59. Zinner MJ, Zuidema GD, Smith P, Mignosa M. The prevention of upper gastrointestinal tract bleeding in patients in an intensive care unit. Surg Gynecol Obstet 1981 153 : 214 20.
60. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004 171 : 33 8.
61. Safdar N, Crnich CJ, Maki DG. The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. Respir Care 2005 50 : 725 39 discussion 739 41.
62. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006 24 : 613 9.
63. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994 269 : 15419 22.
64. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002 41 : 913 58.
65. Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn 2004 31 : 109 34.